Patient-Focused Treatment Decisions in Advanced Non-Small Cell Lung Cancer (NSCLC): Expert Strategies in an Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from June 1, 2020 to August 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer Healthcare, Bristol-Myers Squibb, Lilly, and Merck Sharp & Dohme Corp.

Description:
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it is expected that there will be about 222,500 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 155,870 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. Recent clinical data have demonstrated that NSCLC is a very heterogeneous disease. However, as more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer.

As non-small cell lung cancer therapies and treatments continue to both grow and change, it is imperative that we provide healthcare professionals across all spectrums updated information about both NSCLC itself and the treatment options that can greatly improve a patient's quality of life and prognosis. As the immunotherapies and their indications are changing, the treatment paradigm has grown expansive, making it difficult for clinicians and managed care professionals to make the appropriate decisions based on recent clinical data and guidelines. This program will provide education on the optimal use of current and emerging immunotherapy treatment options and new options that have just become available, ultimately helping patients achieve a greater quality of life and improved clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Examine the rationale underlying the use of immune checkpoint inhibition-based strategies for the management of NSCLC

  • Analyze recent clinical trial data on the use of combination immunotherapy in the first-line treatment of patients with advanced NSCLC

  • Compare and contrast safety and efficacy profiles of current and emerging therapies, both alone and in combination, in the management of advanced NSCLC

  • Determine patient characteristics and companion diagnostic tests that identify patients with advanced NSCLC who may benefit from immune checkpoint inhibitor therapy

  • Discuss managed care considerations of immunotherapy, both alone and in combination with other immunotherapies, by exploring where these options fit into current advanced NSCLC management paradigm

     

Faculty: Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute

Disclosure:

Dr. Socinski serves on an advisory board for Genentech and Spectrum. He has received grant/research support from AbbVie, AstraZeneca, Genentech, Loxo, Novartis, Merck, and Spectrum. He serves on the speaker's bureau for AstraZeneca, Bayer, BMS, Celgene, Guardant, Genentech, and Merck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bayer Healthcare, Bristol-Myers Squibb, Lilly, and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue